Health Catalyst Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
HCAT$1.44-4.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Health Catalyst, Inc. Consolidated Statements Stockholders’ Equit
Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Common Stock and Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · Total Stockholders’ Equity | |||||
|---|---|---|---|---|---|
| Shares · Amount | |||||
| Balance as of January 1, 2021 | 43,376,848 | $1,001,688 | $(725,650) | $61 | $276,099 |
| Public offering, net of underwriters’ discounts and commissions and offering costs | 4,882,075 | 245,180 | — | — | 245,180 |
| Issuance of common stock as acquisition consideration | 762,765 | 43,104 | — | — | 43,104 |
| Issuance of common stock for settlement of contingent consideration | 409,029 | 20,083 | — | — | 20,083 |
| Exercise of stock options | 1,738,027 | 20,350 | — | — | 20,350 |
| Vesting of restricted stock units and restricted shares | 1,316,657 | 2 | — | — | 2 |
| Issuance of common stock under ESPP | 136,679 | 4,837 | — | — | 4,837 |
| Stock-based compensation | — | 65,781 | — | — | 65,781 |
| Net loss | — | — | (153,210) | — | (153,210) |
| Other comprehensive loss | — | — | — | (128) | (128) |
| Balance as of December 31, 2021 | 52,622,080 | $1,401,025 | $(878,860) | $(67) | $522,098 |
| Cumulative effect of adoption of ASU 2020-06 | — | (61,213) | 17,240 | — | (43,973) |
| Vesting of restricted stock units and restricted shares | 2,060,836 | — | — | — | — |
| Issuance of common stock under ESPP | 303,685 | 3,153 | — | — | 3,153 |
| Exercise of stock options | 353,499 | 3,969 | — | — | 3,969 |
| Issuance of common stock for settlement of contingent consideration | 517,575 | 10,052 | — | — | 10,052 |
| Issuance of common stock as acquisition consideration | 113,386 | 3,006 | — | — | 3,006 |
| Repurchase of common stock | (709,139) | (8,393) | — | — | (8,393) |
| Stock-based compensation | — | 73,082 | — | — | 73,082 |
| Net loss | — | — | (137,403) | — | (137,403) |
| Other comprehensive loss | — | — | — | (581) | (581) |
| Balance as of December 31, 2022 | 55,261,922 | $1,424,681 | $(999,023) | $(648) | $425,010 |
| Vesting of restricted stock units and restricted shares | 2,628,206 | — | — | — | — |
| Issuance of common stock under ESPP | 419,680 | 3,588 | — | — | 3,588 |
| Exercise of stock options | 130,710 | 950 | — | — | 950 |
| Repurchase of common stock | (145,027) | (1,808) | — | — | (1,808) |
| Stock-based compensation | — | 56,645 | — | — | 56,645 |
| Net loss | — | — | (118,147) | — | (118,147) |
| Other comprehensive income | — | — | — | 681 | 681 |
| Balance as of December 31, 2023 | 58,295,491 | $1,484,056 | $(1,117,170) | $33 | $366,919 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.